RF Acquisition Corp II (RFAIU) is a Singapore-based blank-check company whose listed securities are units, each consisting of one ordinary share and one right entitling the holder to one-twentieth of a share. The vehicle is pursuing a previously announced combination with Nanyang Biologics, a Singapore-based biotechnology firm backed by The9, in a transaction announced in October 2025 and valued at roughly $1.5 billion. In the latest session, the units fell 6.82%, or $3.00, to $41.00 from a prior close of $44.00 — a confirmed move to the downside. No verified news or fundamental development was identified as the cause.
No verified news or fundamental catalyst found in the public record accounts for the session's decline. There was no business update, no amended transaction filing, no financing announcement, and no analyst rating change published at or before the move. The most recent substantive disclosure was the quarterly report for the period ended September 30, 2026, filed on November 12, which contained no new commercial information and simply restated the status of the pending combination, the depleted trust balance, and the company's going-concern language.
The most likely explanation is mechanical rather than fundamental. With a public float of only about 4.8 million units and daily volume that often runs in the hundreds of shares, the order book is thin enough that a single modest sell order can move the quoted price several percentage points. The decline is also consistent with profit-taking after a run that multiplied the unit price roughly fourfold in three months, and with the wide bid-ask spreads typical of thinly traded micro-cap vehicles. None of these are confirmed causes; they are the patterns the price and volume data support.
Volume was not elevated. Recent sessions have printed anywhere from a few hundred to roughly 5,700 units, and the latest session's early turnover was well below the three-month average — a signature of exhaustion in speculative interest rather than institutional distribution. No sector-wide catalyst was identified: blank-check vehicles as a group had no collective news event at that hour, and the move appears idiosyncratic to this issuer.
Technically, the units remain above the 50-day moving average, which sits near $39.70, while the 200-day average near $20.40 illustrates how far the price has traveled from its trust-anchored base. The $55.00 52-week high established in late August is the key resistance reference; the mid-$30s area, where several recent sessions closed, is the nearest support shelf. The gap between the $41.00 quote and the roughly $11 per-unit redemption value of the trust remains the defining feature of this chart.
The score runs from 0 to 100, where 0 means no meaningful news and a price move entirely normal for the stock, and 100 means transformative news combined with an extreme, rare move. This event scores 8 out of 100.
The news component is minimal: no verified catalyst was found, and the only material disclosure in the period was a routine quarterly filing. The price component is similarly modest. Over the past 60 sessions the units have averaged an absolute daily move of roughly 9%, and 14 of those sessions produced swings of 6.8% or more — meaning the latest decline was actually smaller than the stock's own typical range. Weak news and unremarkable price behavior combine into a low score.
The central variable remains closing the Nanyang Biologics combination, which requires an effective registration statement and Nasdaq listing approval. The termination date has been extended repeatedly, with the sponsor and target funding monthly deposits into the trust; any lapse in that funding would revive liquidation risk. Investors should watch for an amended registration statement, a closing announcement, or another extension. Redemption levels matter as well, since heavy redemptions at prior meetings have already shrunk the trust by more than half. There is no meaningful earnings calendar for an entity with no operations, and no analyst coverage provides a consensus anchor. The dominant risks are deal failure, a collapse of the speculative premium toward trust value, and the persistent illiquidity that magnifies both rallies and sell-offs.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders can help traders compare approach and results before deciding which automated strategies deserve closer attention.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (-543.067). P/E Ratio (0.000) is within average values for comparable stocks, (119.427). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (18.598). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. RFAIU's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. RFAIU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RFAIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry FinancialConglomerates